Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder. An exploratory, randomised, double-blind, international, multicentre study with parallel groups: agomelatine (25 to 50 mg/day) versus escitalopram (10 to 20 mg/day) over a 6-month period.

Trial Profile

Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder. An exploratory, randomised, double-blind, international, multicentre study with parallel groups: agomelatine (25 to 50 mg/day) versus escitalopram (10 to 20 mg/day) over a 6-month period.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Agomelatine (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors IRIS
  • Most Recent Events

    • 24 Nov 2017 Status changed to completed.
    • 10 Oct 2013 Last checked against European Clinical Trials Database record.
    • 28 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top